Keros Therapeutics, Inc. – NASDAQ:KROS

Add to watchlist

$14.5

-1.92

-11.69%

Market closed

Open in about 2 hours

-65.39%

month

-65.39%

quarter

-59.41%

year

Market Cap	693.08M
Enterprise value	682.77M

P/E	-9.71
EV/Sales	N/A
EV/EBITDA	-6.56
Price/Sales	N/A
Price/Book	3.41
PEG ratio	0.15
EPS	-5.4

Revenue	N/A
EBITDA	-169.07M
Income	-160.30M
Revenue Q/Q	N/A
Revenue Y/Y	134%

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Keros Therapeutics Stock Forecast

M Q Y

Last Year

$101

Potential upside: 596.55%

Analysts Price target
Financials & Ratios estimates

Keros Therapeutics, Inc. (NASDAQ:KROS): Profit margin
Jun 2023	0	-37.50M
Sep 2023	8K	-39.44M	-493000%
Dec 2023	143K	-40.24M	-28141.96%
Mar 2024	83K	-43.11M	-51944.58%

Keros Therapeutics, Inc. (NASDAQ:KROS): Debt to assets
Jun 2023	356306000	30.04M	8.43%
Sep 2023	326247000	30.40M	9.32%
Dec 2023	370025000	37.81M	10.22%
Mar 2024	485819000	31.87M	6.56%

Keros Therapeutics, Inc. (NASDAQ:KROS): Cash Flow
Jun 2023	-30.83M	-311K	1.74M
Sep 2023	-33.98M	-550K	284K
Dec 2023	-25.45M	-541K	69.25M
Mar 2024	-44.56M	-946K	156.80M

Keros Therapeutics alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Keros Therapeutics, Inc. (NASDAQ:KROS): Employee count
Aug 2023	107
Sep 2023	121
Oct 2023	121
Nov 2023	121
Dec 2023	129
Jan 2024	129
Feb 2024	129
Mar 2024	136
Apr 2024	136
May 2024	136
Jun 2024	141
Jul 2024	141

Keros Therapeutics
Hedge Funds Holdings Q1 2023

44.96% -32.47%

of KROS is owned by hedge funds

70 -53

hedge funds hold KROS stock

11.34M -8.43M

shares is hold by hedge funds

KROS hedge funds holdings changes

Keros Therapeutics
Insider Trading

Keros Therapeutics, Inc. (NASDAQ:KROS): Insider trades (number of shares)
Period	Buy	Sel
Jun 2023	0	40000
Nov 2023	0	40000

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Option	4 Jan 2024	REGNANTE KEITH officer: Chief Fi..	Employee Stock Option (right to buy)	40,000	$16	$640,000
Option	4 Nov 2023	REGNANTE KEITH officer: Chief Fi..	Common Stock	40,000	$16	$640,000
Sale	4 Nov 2023	REGNANTE KEITH officer: Chief Fi..	Common Stock	40,000	$45.29	$1,811,600
Option	9 Jun 2023	REGNANTE KEITH officer: Chief Fi..	Common Stock	20,000	$16	$320,000
Sale	9 Jun 2023	REGNANTE KEITH officer: Chief Fi..	Common Stock	15,993	$45.03	$720,165
Sale	9 Jun 2023	REGNANTE KEITH officer: Chief Fi..	Common Stock	1,428	$46.46	$66,345
Sale	9 Jun 2023	REGNANTE KEITH officer: Chief Fi..	Common Stock	2,579	$47.25	$121,858
Option	9 Jun 2023	REGNANTE KEITH officer: Chief Fi..	Employee Stock Option (right to buy)	20,000	$16	$320,000
Sale	8 Jun 2023	REGNANTE KEITH officer: Chief Fi..	Common Stock	17,301	$47.66	$824,566
Sale	8 Jun 2023	REGNANTE KEITH officer: Chief Fi..	Common Stock	2,699	$48.65	$131,306

KROS insider trading transactions

Status	Patent	Filling date	Issue date
Application	Application ACTIVIN RECEPTOR TYPE IIA VARIANTS AND METHODS OF USE THEREOF Filling date: 24 May 2021 Issue date: 9 Sep 2021	24 May 2021	9 Sep 2021
Application	Application ALK2 ANTIBODIES AND METHODS OF USE THEREOF Filling date: 22 Apr 2021 Issue date: 19 Aug 2021	22 Apr 2021	19 Aug 2021
Grant	Grant Utility: Activin receptor type IIa variants and methods of use thereof Filling date: 9 Nov 2017 Issue date: 17 Aug 2021	9 Nov 2017	17 Aug 2021
Application	Application CRYSTAL FORMS OF AN ALK2 INHIBITOR Filling date: 23 Apr 2021 Issue date: 5 Aug 2021	23 Apr 2021	5 Aug 2021
Grant	Grant Utility: Activin receptor type IIA variants and methods of use thereof Filling date: 9 Nov 2017 Issue date: 25 May 2021	9 Nov 2017	25 May 2021
Application	Application ACTIVIN RECEPTOR TYPE IIA VARIANTS AND METHODS OF USE THEREOF Filling date: 6 Nov 2020 Issue date: 25 Feb 2021	6 Nov 2020	25 Feb 2021
Application	Application ACTIVIN RECEPTOR TYPE IIA VARIANTS AND METHODS OF USE THEREOF Filling date: 9 Nov 2018 Issue date: 4 Feb 2021	9 Nov 2018	4 Feb 2021
Application	Application ACTIVIN RECEPTOR TYPE IIB VARIANTS AND METHODS OF USE THEREOF Filling date: 9 Jul 2020 Issue date: 31 Dec 2020	9 Jul 2020	31 Dec 2020
Application	Application ACTIVIN RECEPTOR TYPE IIA VARIANTS AND METHODS OF USE THEREOF Filling date: 9 Nov 2017 Issue date: 14 Nov 2019	9 Nov 2017	14 Nov 2019
Application	Application GDNF FUSION POLYPEPTIDES AND METHODS OF USE THEREOF Filling date: 9 Nov 2017 Issue date: 19 Sep 2019	9 Nov 2017	19 Sep 2019

Keros Therapeutics
Executives

Insider	Age	Compensation
Dr. Jasbir Seehra Ph.D. (1955) Pres, Chief Executive Officer, Treasurer, & Director	70	$787,160
Dr. Jennifer Lachey Ph.D. (1972) Chief Scientific Officer	53	$524,920
Mr. Keith C. Regnante (1970) Chief Financial Officer	55	$518,570

Keros Therapeutics
Latest News

Friday, 27 December 2024
10:30	An Investigation Has Commenced on Behalf of Keros Therapeutics, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your KROS Losses	accesswire.com
10:00	Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Keros Therapeutics, Inc. (KROS) And Encourages Shareholders to Reach Out	accesswire.com
Thursday, 26 December 2024
15:30	Shareholder Rights Advocates at Levi & Korsinsky Investigate Keros Therapeutics, Inc. (KROS) Regarding Possible Securities Fraud Violations	accesswire.com
15:00	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Keros Therapeutics, Inc. - KROS	accesswire.com
10:45	An Investigation Has Commenced on Behalf of Keros Therapeutics, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your KROS Losses	accesswire.com
10:00	Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Keros Therapeutics, Inc. (KROS) and Encourages Shareholders to Learn More About the Investigation	accesswire.com
10:00	Keros Therapeutics, Inc. (KROS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation	accesswire.com
07:30	Levi & Korsinsky Reminds Keros Therapeutics, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - KROS	accesswire.com
Tuesday, 24 December 2024
14:45	Lost Money on Keros Therapeutics, Inc. (KROS)? Contact Levi & Korsinsky Regarding an Ongoing Investigation	accesswire.com
14:30	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Keros Therapeutics, Inc. - KROS	accesswire.com
10:15	Lost Money on Keros Therapeutics, Inc.(KROS)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky	accesswire.com
10:00	Bronstein, Gewirtz & Grossman, LLC Encourages Keros Therapeutics, Inc. (KROS) Shareholders to Inquire about Securities Investigation	accesswire.com
Monday, 23 December 2024
10:15	ATTENTION Keros Therapeutics, Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights	accesswire.com
10:00	Bronstein, Gewirtz & Grossman, LLC Is Investigating Keros Therapeutics, Inc. (KROS) And Encourages Investors to Connect	accesswire.com
Sunday, 22 December 2024
11:00	Did Keros Therapeutics, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - KROS	accesswire.com
10:00	Bronstein, Gewirtz & Grossman, LLC Encourages Keros Therapeutics, Inc. (KROS) Stockholders to Inquire about Securities Investigation	accesswire.com
Friday, 20 December 2024
10:30	Levi & Korsinsky Reminds Keros Therapeutics, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - KROS	accesswire.com
10:00	Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Keros Therapeutics, Inc. (KROS) and Encourages Investors to Learn More About the Investigation	accesswire.com
Thursday, 19 December 2024
10:15	Levi & Korsinsky Announces an Investigation on Behalf of Keros Therapeutics, Inc. (KROS) Shareholders Who May Have Been Affected by Fraud	accesswire.com
10:00	Keros Therapeutics, Inc. (KROS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation	accesswire.com
Wednesday, 18 December 2024
10:15	ATTENTION KROS SHAREHOLDERS: Investors who lost money on Keros Therapeutics, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation	accesswire.com
10:00	Bronstein, Gewirtz & Grossman, LLC Is Investigating Keros Therapeutics, Inc. (KROS) And Encourages Investors to Connect	accesswire.com
07:10	Keros Therapeutics: Trading At Essentially Cash Value, Target Of $23 Per Share	seekingalpha.com
Tuesday, 17 December 2024
10:55	Lost Money on Keros Therapeutics, Inc.(KROS)? Contact Levi & Korsinsky Regarding an Ongoing Investigation	accesswire.com
10:30	Keros Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - KROS	accesswire.com
10:30	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Keros Therapeutics, Inc. - KROS	accesswire.com
10:00	Bronstein, Gewirtz & Grossman, LLC Is Investigating Keros Therapeutics, Inc. (KROS) And Encourages Stockholders to Connect	accesswire.com
Monday, 16 December 2024
13:15	Shareholders that lost money on Keros Therapeutics, Inc.(KROS) should contact Levi & Korsinsky about Securities Fraud Investigation - KROS	accesswire.com
12:45	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Keros Therapeutics, Inc. - KROS	accesswire.com
12:15	Levi & Korsinsky Announces an Investigation on Behalf of Keros Therapeutics, Inc. (KROS) Shareholders Who May Have Been Affected by Fraud	accesswire.com

Ideas & Opinions

Seeking Alpha 18 Dec 2024

Keros Therapeutics: Trading At Essentially Cash Value, Target Of $23 Per Share
Seeking Alpha 10 Jun 2024

Keros Therapeutics: Potential Beyond KER-050 For Targeting Of Blood Cancers
Seeking Alpha 2 Aug 2023

Keros Therapeutics: Hematological Therapies Continue To Advance
Seeking Alpha 30 Apr 2023

Keros Therapeutics: Undercovered Company With Data From All Programs
Seeking Alpha 11 Feb 2023

Keros Therapeutics: Market Rewarding KER-050 Trial Momentum

Frequently Asked Questions (FAQ)

What's the price of Keros Therapeutics stock today?

One share of Keros Therapeutics stock can currently be purchased for approximately $14.5.
When is Keros Therapeutics's next earnings date?

Unfortunately, Keros Therapeutics's (KROS) next earnings date is currently unknown.
Does Keros Therapeutics pay dividends?

No, Keros Therapeutics does not pay dividends.
How much money does Keros Therapeutics make?

Keros Therapeutics has a market capitalization of 693.08M.
What is Keros Therapeutics's stock symbol?

Keros Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "KROS".
What is Keros Therapeutics's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Keros Therapeutics?

Shares of Keros Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Keros Therapeutics's key executives?
Keros Therapeutics's management team includes the following people:
- Dr. Jasbir Seehra Ph.D. Pres, Chief Executive Officer, Treasurer, & Director(age: 70, pay: $787,160)
- Dr. Jennifer Lachey Ph.D. Chief Scientific Officer(age: 53, pay: $524,920)
- Mr. Keith C. Regnante Chief Financial Officer(age: 55, pay: $518,570)
How many employees does Keros Therapeutics have?

As Jul 2024, Keros Therapeutics employs 141 workers, which is 4% more then previous quarter.
When Keros Therapeutics went public?

Keros Therapeutics, Inc. is publicly traded company for more then 5 years since IPO on 8 Apr 2020.
What is Keros Therapeutics's official website?

The official website for Keros Therapeutics is kerostx.com.
Where are Keros Therapeutics's headquarters?

Keros Therapeutics is headquartered at 99 Hayden Avenue, Lexington, MA.
How can i contact Keros Therapeutics?

Keros Therapeutics's mailing address is 99 Hayden Avenue, Lexington, MA and company can be reached via phone at +61 73146297.
What is Keros Therapeutics stock forecast & price target?

Based on 3 Wall Street analysts` predicted price targets for Keros Therapeutics in the last 12 months, the avarage price target is $101. The average price target represents a 596.55% change from the last price of $14.5.

Keros Therapeutics, Inc.

kerostx.com

Exchange:

NASDAQ

Full time employees:

160

Industry:

Biotechnology

Sector:

Healthcare

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

+61 73146297

99 Hayden Avenue
Lexington, MA 02421

CIK: 0001664710
ISIN: US4923271013
CUSIP: 492327101